Back

Real-world barriers to long-term ARNI therapy in HFrEF: a one-year analysis of tolerability and dose achievement

30 August 2026 (16:15 - 16:45)
Organised by: Logo
Congress Presentation Part of: Heart failure: diagnosis and therapy Heart Failure with Reduced Ejection Fraction (HFrEF) ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Ms Mariana Santos Silva

Centro Hospitalar do Baixo Vouga, Aveiro (Portugal)

4 More presentations in this session

Presentation thumbnail
Recovered vs remission heart failure among patients with LVEF improvement in non-Ischaemic HFrEF
Doctor T. Nabeta (Sagamihara, JP)
Abstract
Presentation thumbnail
Baseline characteristics of patients with HFrEF on dapagliflozin: final analysis of baseline data from the EVOLUTION-HF DEallEF study HFrEF cohort
Professor B. Assmus (Giessen, DE)
Abstract
Presentation thumbnail
GLP-1 receptor agonists added to guideline-directed medical therapy in heart failure with reduced ejection fraction: a propensity score-matched analysis
Doctor I. Chough (Stony Brook, US)
Abstract
Presentation thumbnail
Cardiopulmonary exercise testing following conduction system versus biventricular pacing in heart failure: a substudy of the PhysioSync-HF randomized trial
Doctor A. Silveira (Porto Alegre, BR)
Abstract

Access the full session

Session thumbnail
Heart failure: diagnosis and therapy

The Event

Event poster

ESC Congress 2026

30 August 2026 16:15 CET
You may be interested in
thumbnail
Congress Presentation
What is the adherence to ARNI and iSGLT2 treatment in heart failure patients with reduced ejection fraction in a real world population?
29 June 2021
thumbnail
Congress Presentation
Patient characteristics and discontinuation patterns amongst renin-angiotensin system inhibitor users in the United Kingdom: analysis using a national primary care database
3 April 2025
thumbnail
Congress Presentation
Safety and tolerability of sacubitril/valsartan in chronic heart failure and reduced ejection fraction: results from the open-label extension of PARADIGM-HF
21 May 2023
thumbnail
Congress Session
Breaking barriers in guideline-based RAASi-therapy: solving issues with hyperkalemia
20 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources